Brought to you by

BMS buys partner ZymoGenetics for $840.6mm
24 Sep 2010
Executive Summary
Bristol-Myers Squibb Co. has acquired publicly traded ZymoGenetics Inc. for $840.6mm, paying just over six times the large-molecule drug developer's 2009 sales. BMS is spending $9.75 (a 90% premium) for each of Zymo's 86.2mm shares outstanding.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com